2025/09/22 by Nazanin Pouya, Natalie A. Finch, Alejandro Granillo +3 · 1 voice
Medicine · Biochemistry, Genetics and Molecular Biology · #Antibiotics Pharmacokinetics and Efficacy #Epilepsy research and treatment #Antibiotic Resistance in Bacteria
paper · doi:10.1128/aac.00674-25
openalex publication_date 2025/09/22 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/25
were treated with intravenous sulbactam-durlobactam as a part of a combination regimen. Penetration into the central nervous system was estimated (by cerebrospinal fluid [CSF]/serum area under the curve [AUC] ratios at steady state) for sulbactam (0.47-0.64) and durlobactam (0.27-0.3), respectively. In view of mostly constant CSF concentrations, single CSF levels at steady state may offer a more convenient and clinically applicable approach for monitoring therapy.